Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Operating Expenses: 2010-2025

Historic Operating Expenses for Sunshine Biopharma (SBFM) over the last 13 years, with Sep 2025 value amounting to $5.0 million.

  • Sunshine Biopharma's Operating Expenses rose 6.31% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 16.52%. This contributed to the annual value of $20.7 million for FY2024, which is 19.96% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Operating Expenses of $5.0 million as of Q3 2025, which was down 23.85% from $6.6 million recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's Operating Expenses peaked at $24.9 million during Q4 2022, and registered a low of $397,842 during Q4 2021.
  • Over the past 3 years, Sunshine Biopharma's median Operating Expenses value was $4.9 million (recorded in 2024), while the average stood at $4.9 million.
  • Per our database at Business Quant, Sunshine Biopharma's Operating Expenses soared by 6,161.52% in 2022 and then slumped by 78.74% in 2023.
  • Quarterly analysis of 5 years shows Sunshine Biopharma's Operating Expenses stood at $397,842 in 2021, then surged by 6,161.52% to $24.9 million in 2022, then tumbled by 78.74% to $5.3 million in 2023, then climbed by 16.59% to $6.2 million in 2024, then increased by 6.31% to $5.0 million in 2025.
  • Its Operating Expenses was $5.0 million in Q3 2025, compared to $6.6 million in Q2 2025 and $5.2 million in Q1 2025.